QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Enzyme Replacement Therapies—Classification and Pharmacovigilance

Test your understanding of the concepts covered by Enzyme Replacement Therapies: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should therapeutic enzymes not automatically be treated as a single pharmacovigilance class?

Only non-recombinant enzymes can cause adverse reactions Products may differ in structure, manufacturing process, cellular uptake, indication and patient population All therapeutic enzymes have identical immunogenicity patterns Class effects are prohibited under EU pharmacovigilance principles

Question 2 of 10 Which statement best distinguishes a safety observation from a safety hypothesis?

A reported infusion reaction is an observation; attributing it to a specific immune mechanism is a hypothesis requiring evidence A safety observation is valid only when causality is already established A hypothesis is simply a confirmed observation written in technical language Antibody detection is automatically a causal conclusion

Question 3 of 10 How should biochemical biomarker changes generally be used in ERT safety and efficacy assessment?

They may provide evidence of biological activity but should not automatically be treated as proof of patient benefit They are always more reliable than clinical outcomes They are irrelevant to assessment of reduced response They establish causality for any adverse event occurring after treatment

Question 4 of 10 Which evidence combination would most strengthen a hypothesis that anti-drug antibodies contributed to reduced ERT response?

A positive antibody test with no clinical or biological change Antibody development temporally associated with reduced exposure or enzyme activity and a corresponding loss of clinical or biomarker response A single infusion reaction before antibody testing A manufacturing change with no information about patient exposure or response

Question 5 of 10 Which case information is particularly important when evaluating a reaction that occurred after restarting ERT following a treatment interruption?

Only the patient’s age at original diagnosis The interruption duration, prior tolerance, re-exposure timing and reaction onset Only the batch number of the first lifetime dose Whether the product belongs to the wider therapeutic-enzyme category

Question 6 of 10 Which statement best describes the pharmacovigilance significance of anti-drug antibodies?

Their presence always proves clinically meaningful immunogenicity They are irrelevant unless a hypersensitivity reaction occurs They should be interpreted together with titre, timing, persistence and clinical, pharmacokinetic or pharmacodynamic findings They automatically establish loss of efficacy

Question 7 of 10 A patient develops fever, flushing and hypotension during an ERT infusion. Which conclusion is most scientifically appropriate at case intake?

The event is an observation of an administration-related reaction; its precise mechanism remains to be assessed The event is definitively an IgE-mediated allergy The event is necessarily caused by neutralising antibodies The event should be classified as disease progression because the symptoms are nonspecific

Question 8 of 10 A patient switches from one biological enzyme product to another and later reports reduced response. What is the best approach?

Automatically attribute the reduced response to the newly introduced product Ignore the prior product because only current exposure is relevant Reconstruct sequential exposure and assess disease course, interruptions, adherence, immune findings and product-specific information Consider the report uninterpretable unless a batch defect is identified

Question 9 of 10 A manufacturing process is changed to increase production capacity, but no clinical safety observation has emerged. Which statement is most appropriate?

The change automatically constitutes a pharmacovigilance signal The change is assessed through quality and regulatory comparability processes; pharmacovigilance remains relevant if safety evidence or a clinical hypothesis emerges The change can be ignored because manufacturing cannot affect biological products A new risk must be declared solely because the product is recombinant

Question 10 of 10 Which statement best expresses the relationship between ERT-specific considerations and the EU pharmacovigilance framework?

ERT requires an entirely separate pharmacovigilance system outside general GVP General pharmacovigilance requirements remain applicable, with biological-product characteristics informing product-specific assessment Only quality requirements apply because ERT products are biological ERT-specific scientific considerations replace the need for signal management and risk management

QPPV.com

Knowledge Assessment: Enzyme Replacement Therapies—Classification and Pharmacovigilance

Cookie Settings